|Articles|June 13, 2023
Transduction for AAV with Sean Hart
Author(s)Chris Spivey
Chris Spivey, editorial director, speaks with Sean Hart, CEO and SCO of LumaCyte, on percent transduction for AAV measured.
Advertisement
Chris Spivey, editorial director, speaks with Sean Hart, CEO and SCO of LumaCyte, on percent transduction for AAV measured. The full discussion can and more can be viewed
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
3
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
4
High-Dose Nusinersen Slows Neurodegeneration in SMA Patients, Study Shows
5